Pricing Log in Create free account
Friday 6 November 2026 Export GRAL’s income statement to Excel — free account

GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

127.85 8.72 +7.32%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

GRAIL, Inc. (GRAL) Debt to equity

Alert me on Debt to equity

GRAIL, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). That is below the Diagnostics & Research industry median of 0.0× and in line with the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
11 more quarters

Debt to equity against peers

Company Debt to equity
VCYT Veracyte, Inc. compare 0.0×
CDNA CareDx, Inc. compare 0.0×
GRAL GRAIL, Inc. 0.0×
BLLN BillionToOne, Inc. compare 0.0×
ADPT Adaptive Biotechnologies Corporation compare 0.0×
ICLR ICON PLC compare 0.4×
QGEN QIAGEN N.V. compare 0.5×
RDNT RadNet, Inc. compare 0.9×
SHC Sotera Health Company compare 3.1×
Diagnostics & Research industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on GRAL